Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Correction (v174,p1874) Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simpson, S. H. Articles by Johnson, J. A. Search for Related Content PubMed PubMed Citation Articles by Simpson, S. H. Articles by Johnson, J. A. Related Collections Drugs: cardiovascular system Diabetes Related Article

Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

From the Institute of Health Economics (all authors); the Faculty of Pharmacy and Pharmaceutical Sciences (Simpson, Tsuyuki); the Divisions of General Internal Medicine (Majumdar) and Cardiology (Tsuyuki), Department of Medicine; and the Department of Public Health Sciences (Majumdar, Tsuyuki, Eurich, Johnson), University of Alberta, Edmonton, Alta.

Correspondence to: Dr. Jeffrey A. Johnson, 10405 Jasper Ave., Rm. 1200, Edmonton AB T5J 3N4; fax 780 448-0018; jeff.johnson{at}ualberta.ca

Background: Over the past 30 years, the relation between use of sulfonylureas to treat type 2 diabetes and the risk of cardiovascular events has been vigorously debated. The purpose of this study was to determine if the risk of death changes with level of exposure to sulfonylurea drugs.

Methods: This was a retrospective, inception cohort study using administrative data from Saskatchewan Health (1991– 1999). The 5795 subjects, identified by their first-ever dispensation for an oral antidiabetic agent, were grouped according to their use of such agents during follow-up. Potential subjects using insulin or combination therapy were excluded. Exposure level was defined by daily dose and degree of adherence. Separate multivariate Cox proportional-hazard models were constructed for each monotherapy group and used to calculate the risk of death associated with higher versus lower exposure category. Disease severity indicators were identified among the administrative data and entered as covariates in each model. The main outcomes were all-cause mortality and death from an acute ischemic event.

Results: The mean age of the cohort members was 66.3 (standard deviation [SD] 13.4) years; 43.4% were female; and their mean duration of follow-up was 4.6 (SD 2.1) years. First-generation sulfonylureas were used exclusively by 120 subjects; glyburide, by 4138; and metformin, by 1537. A greater risk of death was associated with higher daily doses of the first-generation sulfonylureas (adjusted hazard ratio [HR] 2.1, 95% confidence interval [CI] 1.0–4.7) and glyburide (HR 1.3, 95% CI 1.2–1.4), but not metformin (HR 0.8, 95% CI 0.7–1.1). Similar associations were observed for death caused by an acute ischemic event.

Interpretation: Higher exposure to sulfonylureas was associated with increased mortality among patients newly treated for type 2 diabetes. The same relation was not observed with metformin. This implies that the manner in which blood glucose concentration is lowered may be as important as achieving recommended glucose targets.

This article has been cited by other articles:

				I. Tzoulaki, M. Molokhia, V. Curcin, M. P Little, C. J Millett, A. Ng, R. I Hughes, K. Khunti, M. R Wilkins, A. Majeed, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ, December 3, 2009; 339(dec03_1): b4731 - b4731. [Abstract] [Full Text] [PDF]

				S. A. Kassem and I. Raz Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No Diabetes Care, November 1, 2009; 32(suppl_2): S337 - S341. [Full Text] [PDF]

				D. A. Lamb, D. T. Eurich, F. A. McAlister, R. T. Tsuyuki, W. M. Semchuk, T. W. Wilson, and D. F. Blackburn Changes in Adherence to Evidence-Based Medications in the First Year After Initial Hospitalization for Heart Failure: Observational Cohort Study From 1994 to 2003 Circ Cardiovasc Qual Outcomes, May 1, 2009; 2(3): 228 - 235. [Abstract] [Full Text] [PDF]

				J. Z. Duan Two Commonly Used Methods for Exposure-Adverse Events Analysis: Comparisons and Evaluations J. Clin. Pharmacol., May 1, 2009; 49(5): 540 - 552. [Abstract] [Full Text] [PDF]

				J. W. M. Cheng, S. H. Bhatt, and J. D. Goldman-Levine The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease Journal of Pharmacy Practice, April 1, 2009; 22(2): 179 - 193. [Abstract] [PDF]

				F. A. McAlister, D. T. Eurich, S. R. Majumdar, and J. A. Johnson The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy Eur J Heart Fail, July 1, 2008; 10(7): 703 - 708. [Abstract] [Full Text] [PDF]

				E. Standl and O. Schnell Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted? Diabetes Care, February 1, 2008; 31(Supplement_2): S136 - S139. [Full Text] [PDF]

				L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, L. Ryden, and for the DIGAMI 2 Investigators The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial Eur. Heart J., January 2, 2008; 29(2): 166 - 176. [Abstract] [Full Text] [PDF]

				D. T Eurich, F. A McAlister, D. F Blackburn, S. R Majumdar, R. T Tsuyuki, J. Varney, and J. A Johnson Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ, September 8, 2007; 335(7618): 497 - 497. [Abstract] [Full Text] [PDF]

				M. C. Granberry, J. B. Hawkins, and A. M. Franks Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure Am. J. Health Syst. Pharm., May 1, 2007; 64(9): 931 - 936. [Abstract] [Full Text] [PDF]

				S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443. [Abstract] [Full Text] [PDF]

				R. A Ajjan and P. J Grant Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 147 - 158. [Abstract] [PDF]

				R. Lehman Evidently... Evid. Based Med., August 1, 2006; 11(4): 102 - 102. [Full Text] [PDF]

				Other articles noted Evid. Based Med., August 1, 2006; 11(4): 127 - 128. [Full Text] [PDF]

				P. Valensi and G. Slama Review: Sulphonylureas and cardiovascular risk: facts and controversies The British Journal of Diabetes & Vascular Disease, July 1, 2006; 6(4): 159 - 165. [Abstract] [PDF]

				S. Lofsky Patient characteristics not described Can. Med. Assoc. J., June 20, 2006; 174(13): 1874 - 1874. [Full Text] [PDF]

				Do Sulfonylureas Increase Mortality? Journal Watch (General), February 3, 2006; 2006(203): 1 - 1. [Full Text]

				D. S.H. Bell Do sulfonylurea drugs increase the risk of cardiac events? Can. Med. Assoc. J., January 17, 2006; 174(2): 185 - 186. [Full Text] [PDF]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2006, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.